Anxiety is one of the most prevalent conditions of modern life, yet the pharmacological tools most commonly used to treat it come with a significant cost: sedation, cognitive impairment, tolerance, physical dependence, and withdrawal syndromes that can be worse than the original condition. For decades, researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences have been developing a different kind of answer — a synthetic peptide called Selank that modulates anxiety through the brain's own regulatory systems, without the liabilities that define conventional anxiolytics.
What Is Selank?
Selank is a synthetic heptapeptide — a chain of seven amino acids — with the sequence Thr–Lys–Pro–Arg–Pro–Gly–Pro. It was developed as a structural analogue of tuftsin, an endogenous tetrapeptide (Thr–Lys–Pro–Arg) that is naturally produced in the spleen and is known for its immunomodulatory properties. By extending the tuftsin sequence and modifying its terminal residues, researchers created a compound with substantially greater pharmacological activity, improved stability, and a prolonged duration of action compared to its parent molecule.
Selank was registered as a pharmaceutical drug in Russia in 2009 and in Ukraine in 2014, where it is prescribed for generalized anxiety disorder, anxiety-asthenic states, and neurasthenia. In the research context, it has been administered both intranasally and as a subcutaneous injection, with the intranasal route being the standard clinical delivery method. Its development spans more than three decades of preclinical and clinical investigation, making it one of the most thoroughly studied peptide anxiolytics in the world.[1]
How Selank Works: The GABA Connection
The primary mechanism underlying Selank's anxiolytic action involves allosteric modulation of GABA-A receptors — the same receptor family targeted by benzodiazepines. However, Selank does not bind to the benzodiazepine site directly. Instead, it acts as an allosteric modulator that changes the receptor's affinity for endogenous GABA, enhancing inhibitory neurotransmission through a more physiologically precise mechanism. This distinction is critical: it explains why Selank produces anxiolytic effects comparable to benzodiazepines in clinical trials, while avoiding the sedation, muscle relaxation, and dependence that characterize that drug class.
A 2016 transcriptomic study published in Frontiers in Pharmacology provided molecular confirmation of this mechanism. Researchers analyzed the gene expression profiles of 84 genes involved in GABAergic neurotransmission following Selank administration and found a strong positive correlation between Selank's effects and GABA's own gene expression profile at one hour post-administration. Notably, Selank's effects on gene expression persisted at three hours — beyond GABA's own timeline — suggesting that the peptide also activates downstream signaling pathways that extend and amplify the initial GABAergic response.[2]
Clinical Evidence: Anxiety Without Sedation
The most significant clinical validation of Selank comes from a double-blind, randomized controlled trial comparing Selank to medazepam — a standard benzodiazepine — in patients with generalized anxiety disorder and neurasthenia. Published in 2008, this trial found that Selank produced anxiolytic effects comparable to medazepam across all primary outcome measures. The critical difference was in the side effect profile: Selank produced no sedation, no muscle relaxation, no tolerance development, and no withdrawal syndrome upon discontinuation. Patients in the Selank group also demonstrated improvements in cognitive function — including attention and memory — that were not observed in the benzodiazepine group.[3]
A 2017 study published in Behavioural Neurology examined Selank's interaction with diazepam in a chronic unpredictable mild stress model. The researchers found that Selank not only produced anxiolytic effects on its own, but also significantly enhanced diazepam's anxiolytic action when the two were combined — without increasing sedation. After 14 days of daily Selank administration, no tolerance was observed, a finding that stands in sharp contrast to the rapid tolerance development seen with benzodiazepines.[4]
"Selank produced anxiolytic effects comparable to medazepam in patients with generalized anxiety disorder, with no sedation, no tolerance, and no withdrawal syndrome — while simultaneously improving cognitive function." — Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008
BDNF Upregulation: A Neuroprotective Bonus
One of the more remarkable findings in the Selank literature involves its effects on brain-derived neurotrophic factor (BDNF) — a protein that is essential for the survival of existing neurons, the growth of new ones, and the synaptic plasticity that underlies learning and memory. BDNF expression in the hippocampus is suppressed by chronic stress, which is one of the mechanisms by which prolonged anxiety damages cognitive function over time.
A 2008 study published in Doklady Biological Sciences demonstrated that intranasal administration of Selank at doses of 250 and 500 µg/kg significantly increased both BDNF mRNA and BDNF protein levels in the rat hippocampus — measured at 1, 3, and 24 hours post-administration. The researchers concluded that Selank's ability to stimulate BDNF expression in the hippocampus represents a key mechanism by which the peptide exerts its combined anxiolytic and nootropic effects on the central nervous system.[5] This finding is particularly significant because it suggests that Selank does not merely suppress anxiety symptoms, but may actively counteract the neurobiological damage that chronic anxiety inflicts on the brain.
Neurotransmitter Modulation Beyond GABA
Selank's pharmacological profile extends beyond GABAergic modulation. Research has documented its effects on serotonergic, dopaminergic, and enkephalinergic systems — a breadth of action that helps explain its combination of anxiolytic and cognitive-enhancing properties. The 2016 transcriptomic study identified activation of dopamine receptor genes (Drd1a, Drd2, Drd5), which are associated with reward processing, motivation, and synaptic plasticity. Selank also inhibits the enzymes responsible for degrading enkephalins — endogenous opioid peptides that play a role in stress regulation and mood — thereby prolonging their activity and contributing to the peptide's anxiolytic effect through a second, independent pathway.[2]
This multi-target pharmacology distinguishes Selank from single-mechanism anxiolytics and may account for its clinical observation that anxiety relief is accompanied by cognitive improvement rather than impairment — a combination that is pharmacologically unusual and clinically valuable.
Safety Profile
Across the clinical and preclinical literature, Selank has demonstrated a consistently favorable safety profile. No sedation, no muscle relaxation, no tolerance, no withdrawal syndrome, and no addiction potential have been reported in any published trial. Cognitive function is preserved or enhanced rather than impaired. The peptide is well-tolerated at therapeutic doses, with no severe adverse events documented in treatment studies. Its derivation from an endogenous immunomodulatory peptide (tuftsin) and its rapid enzymatic metabolism contribute to its benign safety profile.
Editorial Note: Selank is not currently available at Nectar Wellness. This article is provided for educational purposes only. We are actively monitoring the research and may offer Selank in the future as the evidence base continues to develop.